PROMETRIKA and Karyopharm: Partners in Global COVID-19 Trial
Karyopharm Therapeutics Inc. (KPTI)
Last karyopharm therapeutics inc. earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.karyopharm.com/investor-relations
Company Research
Source: Business Wire
Cambridge, MA-based clinical research organization to be responsible for Clinical Trial Site Management and On-Site Monitoring in the United States CAMBRIDGE, Mass.--(BUSINESS WIRE)--PROMETRIKA (www.prometrika.com), a leading clinical research organization, is collaborating with Karyopharm Therapeutics (Nasdaq: KPTI) to conduct the first randomized clinical trial for low-dose selinexor (XPOVIO®), an XPO1 inhibitor, in hospitalized patients with severe COVID-19.PROMETRIKA will be responsible for US clinical trial site management and on-site monitoring, ensuring collection of accurate and actionable high-quality data. In total, 230 patients will be enrolled into the trial worldwide.Karyopharm and PROMETRIKA are working closely with investigators and hospital sites at unprecedented speed to accurately capture the data needed to fast-track early findings. The goal is to add to the body of evidence that XPO1 inhibitors may play an important role in treating people with this life-threate
Show less
Read more
Impact Snapshot
Event Time:
KPTI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KPTI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KPTI alerts
High impacting Karyopharm Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
KPTI
News
- Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR Newswire
- Karyopharm to Participate at the Piper Sandler 37th Annual Healthcare ConferencePR Newswire
- Looking at the Narrative for Karyopharm as Financing and Trial Milestones Shift the Outlook [Yahoo! Finance]Yahoo! Finance
- What Recent Analyst Forecasts Mean for the Changing Story Behind Karyopharm Therapeutics [Yahoo! Finance]Yahoo! Finance
- Karyopharm Therapeutics Inc (KPTI) Q3 2025 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]Yahoo! Finance
KPTI
Earnings
- 11/3/25 - Miss
KPTI
Sec Filings
- 11/24/25 - Form 424B3
- 11/24/25 - Form 424B3
- 11/14/25 - Form SCHEDULE
- KPTI's page on the SEC website